NCT04183283CompletedPhase 1
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Oral Single-Doses of LY3526318 on Cinnamaldehyde-Induced Dermal Blood Flow in Healthy Females
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 16
- Locations
- 1
- Primary Endpoint
- Decrease in Cinnamaldehyde (CA)-Induced Dermal Blood Flow (DBF) Relative to Placebo Measured by Laser Doppler Imaging (LDI) at 3 Hours Post-dose (LDI)
Study Overview
Brief Summary
The main purpose of this study is to learn more about how LY3526318 affects blood flow to the skin in healthy women. For each participant, the study will last up to 28 days and Part B will last up to 78 days, including screening and follow-up.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Basic Science
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 45 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Must be healthy female participants as determined by medical history and physical examination
- •-Female participants must be nonpregnant and not lactating, or of nonchildbearing potential (either surgically sterilized [for example (e.g.) tubal occlusion, hysterectomy, bilateral salpingectomy] or physiologically incapable of becoming pregnant, or postmenopausal with amenorrhea for at least 12 consecutive months)
- •Must have a body-mass index of 18 to 30 kilograms per square meter, inclusive
- •Must be willing to follow specific study procedures including
- •No drugs (except study drug, hormonal contraceptives) 7 days prior to each assessment and until discharge from Clinical Research Unit (CRU)
- •No chocolate, alcohol, or caffeine containing products 24 hours prior to initiation of each assessment and until discharge
- •A complete 4 hour fast (water is allowed) prior to cinnamaldehyde (CA) assessment
- •Must have suitable skin characteristics for the dermal CA challenge procedures and measured through Laser Doppler Imaging (LDI)
Exclusion Criteria
- •Must not be currently enrolled in or discontinued within the last 30 days or 5 half-lives of the study drug (whichever is longer), from a clinical study involving an investigational product or any type of medical research judged not compatible with this study
- •Must not have received treatment with biological agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing
- •Must not have a history or presence of medical illness including, but not limited to, any cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric or neurological disease, convulsions, or any clinically significant laboratory abnormality that would preclude study participation
- •Must not have an abnormality in the 12-lead electrocardiogram (ECG) or confirmed Frederica's corrected QT interval greater than (>) 470 millisecond (msec)
- •Must not have a history of clinically significant multiple or severe drug allergies or severe post-treatment hypersensitivity reactions
- •Must avoid excessive tanning
- •Must not use lotions, oils, depilatory preparations, makeup, or other topical treatments on the arms on a regular basis or have used any topical treatments within 7 days prior to start of the first study day
- •Must not be a habitual and heavy consumer of coffee or caffeinated beverages (more than approximately 4 cups of tea, coffee, or cola drinks/day) or who cannot refrain from caffeinated beverages 24 hours prior to CA application
- •Must not be drinking alcohol 24 hours prior to each assessment
- •Must not be around second-hand smoke 24 hours prior to CA application or use nicotine-containing products. Ex-smokers should have ceased smoking at least 6 months
Arms & Interventions
LY3526318
Experimental
10 milligrams (mg), 30 mg and 100 mg LY3526318 administered orally in three of four study periods.
Intervention: LY3526318 (Drug)
Placebo
Placebo Comparator
Placebo administered orally in one of four study periods.
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Decrease in Cinnamaldehyde (CA)-Induced Dermal Blood Flow (DBF) Relative to Placebo Measured by Laser Doppler Imaging (LDI) at 3 Hours Post-dose (LDI)
Time Frame: 3 hours post LY3526318 dose (pre-CA challenge), 3.3 hours post LY3526318 dose (post-CA challenge)
CA-induced DBF was measured by laser doppler imaging (LDI). Least Squares (LS) mean was determined by analysis of variance (ANOVA) model with treatment, period, sequence, time and treatment\*time interaction as fixed factors and subject within sequence as a random factor.
Secondary Outcomes
- Decrease in CA-induced Dermal Blood Flow (DBF) Relative to Placebo Measured by Laser Speckle Contrast Imaging (LSCI) at 3 Hours Post-dose (LSCI)(3 hours post LY3526318 dose (pre-CA challenge), 3.3 hours post LY3526318 dose (post-CA challenge))
- Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3526318(Predose, 3 hours and 24 hours after each LY3526318 dose (days 1 through 50))
- PK: Maximum Observed Drug Concentration (Cmax) of LY3526318(Predose, 3 hours and 24 hours after each LY3526318 dose (days 1 through 50))
- Plasma Concentrations of LY3526318 at 3 and 24 Hours(3 hours and 24 hours post dose)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With OsteoarthritisOsteo Arthritis KneeOsteoarthritisNCT05080660Eli Lilly and Company160
Completed
Phase 2
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic PainDiabetic Peripheral Neuropathic PainNCT05177094Eli Lilly and Company155
Completed
Phase 1
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or ObeseOverweightNCT06039826Eli Lilly and Company46
Completed
Phase 2
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic ArthritisArthritis, PsoriaticNCT02719171AbbVie185
Completed
Phase 3
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary AngioedemaHereditary Angioedema (HAE)NCT02584959Shire75